In managing a patient with type 2 diabetes whose BMI is 34 kg/m2 and A1C is 8.2%, the most appropriate treatment option is?

Adding a GLP-1 agonist is a suitable treatment option for this patient due to several advantageous features of these medications in the context of type 2 diabetes management, particularly for individuals who are overweight or obese.

GLP-1 agonists, such as liraglutide or semaglutide, not only aid in lowering blood glucose levels but also have the added benefit of promoting weight loss, which is significant given this patient's BMI of 34 kg/m². Weight management is crucial in type 2 diabetes management, as excess weight can exacerbate insulin resistance and complicate glycemic control.

Furthermore, GLP-1 agonists work by stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon release, which contributes to their effectiveness in reducing A1C levels. Since this patient has an A1C of 8.2%, which indicates inadequate glycemic control, incorporating a GLP-1 agonist can help achieve better metabolic outcomes.

In addition, GLP-1 agonists have a favorable cardiovascular profile, providing additional benefits for patients with type 2 diabetes, who are often at a higher risk for cardiovascular diseases. This aligns with the current treatment guidelines, which advocate for using agents that positively affect weight and cardiovascular